image cradit: Goulburn Helth hub
The electroencephalography (EEG) devices market is expected to reach USD 1.19 Billion by 2021 from USD 0.85 Billion in 2016, at a CAGR of 6.7%. The growth of this market is driven by the increasing incidence of epilepsy and sleep disorders, growing number of initiatives to increase awareness about EEG, and technological advancements in EEG devices. However, the high cost associated with these procedures and lack of trained professionals are restraining the growth of this market to some extent.
EEG devices are used for detection and diagnosis of various neurological conditions such as epilepsy, sleep disorders, Alzheimer’s disease, dementia, head injury, etc. These devices help in providing information about the electrical activity going on in the brain through electrodes placed on the scalp. This procedure is painless and safe for patients.
The electroencephalography (EEG) devices market is projected to reach USD 1.85 billion by 2023 from USD 1.31 billion in 2018, at a CAGR of 7.3%. The EEG devices market is segmented on the basis of product, application, end user, and region.
On the basis of product, the EEG devices market is classified into standalone/portable EEG devices and ambulatory/wearable EEG devices.
The standalone/portable EEG device segment accounted for the largest share of the global EEG devices market in 2017. Standalone or portable EEGs offer several advantages over ambulatory or wearable EEGs such as lower cost, easy availability, portability, ease-of-use, and shorter acquisition time. However, technological advances have resulted in the development of miniature ambulatory/wearable EEGs that offer similar features as standalone/portable EEGs but are more comfortable to use as they can be worn for long periods without causing any discomfort.
The applications segment includes brain mapping, neurofeedback therapy (NFT), sleep disorder diagnosis & treatment monitoring, epilepsy diagnosis & monitoring, and others (including dementia & Alzheimer's disease diagnosis). The brain mapping application segment held the largest share of the global EEG devices market in 2017 owing to increasing research activities related to brain mapping along with growing number of initiatives by government organizations and private companies to promote brain mapping studies. In addition, rising prevalence of neurological disorders is another major factor driving growth of this application segment of the global EEGdevicesmarket during forecast period .
The standalone/portable EEG device segment accounted for the largest share of the global EEG devices market in 2017. Standalone or portable EEGs offer several advantages over ambulatory or wearable EEGs such as lower cost, easy availability, portability, ease-of-use, and shorter acquisition time. However, technological advances have resulted in the development of miniature ambulatory/wearable EEGs that offer similar features as standalone/portable EEGs but are more comfortable to use as they can be worn for long periods without causing any discomfort.
The applications segment includes brain mapping, neurofeedback therapy (NFT), sleep disorder diagnosis & treatment monitoring, epilepsy diagnosis & monitoring, and others (including dementia & Alzheimer's disease diagnosis). The brain mapping application segment held the largest share of the global EEG devices market in 2017 owing to increasing research activities related to brain mapping along with growing number of initiatives by government organizations and private companies to promote brain mapping studies. In addition, rising prevalence of neurological disorders is another major factor driving growth of this application segment of the global EEGdevicesmarket during forecast period .
Can Be Used Eeg for Diagnosis Purpose Or in Treatment Purpose?
Yes, EEG can be used for diagnosis and treatment purposes. EEG is often used to diagnose epilepsy, sleep disorders, and other neurological conditions. It can also be used to help guide treatment decisions.
What are the Contraindications of Eeg?
EEG, or electroencephalography, is a diagnostic test used to assess electrical activity in the brain. It is often used to diagnose seizures or epilepsy. EEG may also be used to help determine the cause of other neurological symptoms, such as dizziness, headache, and memory problems.
There are some contraindications to having an EEG. These include: -metal implants or devices in the body, such as pacemakers or cochlear implants
-implanted electronic devices, such as vascular access ports or cerebral aneurysm clips -pregnancy -bleeding disorders.
There are some contraindications to having an EEG. These include: -metal implants or devices in the body, such as pacemakers or cochlear implants
-implanted electronic devices, such as vascular access ports or cerebral aneurysm clips -pregnancy -bleeding disorders.
Conclusion.
The electroencephalography devices market is expected to grow at a CAGR of around 7.5% during the forecast period of 2020-2025. The major factors driving the growth of this market are the rising number of neurological disorders and the increasing demand for early diagnosis of these disorders.
In terms of geography, North America is expected to be the largest market for electroencephalography devices, followed by Europe and Asia-Pacific.
The growing prevalence of epilepsy and sleep disorders in North America is one of the key factors driving the growth of this market in the region. Some of the major players operating in this market include Nihon Kohden Corporation, Cadwell Laboratories Inc., NeuroLogica Corporation, Cas Medical Systems Inc., Natus Medical Incorporated, Ametek Inc., Advanced Neuro Monitoring LLC, Compumedics Limited, ika Systems GmbH, and Biosemi BV.
The growing prevalence of epilepsy and sleep disorders in North America is one of the key factors driving the growth of this market in the region. Some of the major players operating in this market include Nihon Kohden Corporation, Cadwell Laboratories Inc., NeuroLogica Corporation, Cas Medical Systems Inc., Natus Medical Incorporated, Ametek Inc., Advanced Neuro Monitoring LLC, Compumedics Limited, ika Systems GmbH, and Biosemi BV.